Abstracts tagged "PAD and rheumatoid arthritis (RA)"

Abstract Number: 571 • 2016 ACR/ARHP Annual Meeting
High Titer Rheumatoid Arthritis Antibodies Distinguish Between PAD2 and PAD4 Citrullinated Fibrinogen
Nathalie Blachere^1,2, Salina Parveen¹, Mayu Frank¹, Brian D. Dill¹, Henrik Molina¹ and Dana E. Orange^1,3,4, ¹The Rockefeller University, New York, NY, ²Howard Hughes Medical Institute, Chevy Chase, MD, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴The New York Genome Center, New York, NY
Background/Purpose: Most patients with rheumatoid arthritis (RA) harbor antibodies to citrullinated autoantigens, such as citrullinated fibrinogen. Two isoforms of peptidylarginine deiminase (PAD), PAD2 and PAD4,…
Abstract Number: 1612 • 2015 ACR/ARHP Annual Meeting
Association of Single Nucleotide Polymorphisms of PADI4 and HLA-DRB1 Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases
Seung-Cheol Shim¹, In-Seol Yoo², Su-Jin Yoo¹, Young Kim¹, Jinhyun Kim³ and Seong-Wook Kang², ¹Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ³Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea
Background/Purpose: Lung diseases (LD) are common extra-articular manifestations in rheumatoid arthritis (RA). Recent studies have shown the association of RA-LD with anti-citrullinated protein antibodies. The…
Abstract Number: 2922 • 2014 ACR/ARHP Annual Meeting
Association of Single Nucleotide Polymorphisms of PADI4 Gene with Susceptibility to Rheumatoid Arthritis-Related Lung Disease
Seong-Wook Kang¹, Seung-Taek Song¹, Song Soo Kim², Ji Young Kim¹, So Young Lee¹, Su-Jin Yoo³, In-Seol Yoo¹, Jinhyun Kim¹ and Seung-Cheol Shim¹, ¹Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Radiology, Chungnam National University School of Medicine, Daejeon, South Korea, ³Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea
Background/Purpose Rheumatoid arthritis (RA) causes a myriad of pulmonary complications, including bronchiolitis and bronchiectasis, pleuritis, and interstitial lung disease (ILD). Recently, several studies have shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].